Drug_A_Name,Drug_B_Name,Drug_A_Class,Drug_B_Class,DrugBank_Severity,DrugBank_Text,Final_Severity,XAI_Rule_A_Mortality,XAI_Rule_B_Tolerability,XAI_Rule_C_CCB_RAAS_Combo,XAI_Rule_D_Diuretic,XAI_Rule_E_BetaBlocker,XAI_Combined_Clinical_Notes
Captopril,Enalapril,ACEI,ACEI,Moderate,"DESCRIPTION

The excretion of Captopril can be decreased when combined with Enalapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Lisinopril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Lisinopril is combined with Captopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Perindopril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Perindopril is combined with Captopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Ramipril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Ramipril is combined with Captopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Imidapril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Captopril is combined with Imidapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Candesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Captopril is combined with Candesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Irbesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Captopril is combined with Irbesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Losartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Captopril is combined with Losartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Telmisartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Captopril is combined with Telmisartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Valsartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Captopril is combined with Valsartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Olmesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Captopril is combined with Olmesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Captopril,Acebutolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Acebutolol may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Captopril,Atenolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Atenolol may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Captopril,Betaxolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Betaxolol may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Captopril,Bisoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Bisoprolol may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Captopril,Metoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Metoprolol may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Captopril,Nebivolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Captopril may increase the hypotensive activities of Nebivolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Captopril,Propranolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Propranolol may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Captopril,Amlodipine,ACEI,CCB,Minor,"DESCRIPTION

Amlodipine may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Captopril,Felodipine,ACEI,CCB,Minor,"DESCRIPTION

Felodipine may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Captopril,Isradipine,ACEI,CCB,Minor,"DESCRIPTION

Isradipine may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Captopril,Lercanidipine,ACEI,CCB,Moderate,"DESCRIPTION

The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Captopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Captopril,Nifedipine,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Nifedipine is combined with Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Captopril,Diltiazem,ACEI,CCB,Minor,"DESCRIPTION

Diltiazem may increase the hypotensive activities of Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Captopril,Verapamil,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Captopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Captopril,Hydrochlorothiazide,ACEI,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Captopril,Indapamide,ACEI,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Captopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Captopril,Amiloride,ACEI,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Amiloride is combined with Captopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Lisinopril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Enalapril is combined with Lisinopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Perindopril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Enalapril is combined with Perindopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Ramipril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Ramipril is combined with Enalapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Imidapril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Enalapril is combined with Imidapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Candesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalapril is combined with Candesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Irbesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalapril is combined with Irbesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Losartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalapril is combined with Losartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Telmisartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalapril is combined with Telmisartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Valsartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalapril is combined with Valsartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Olmesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalapril is combined with Olmesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Enalapril,Acebutolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Enalapril may increase the hypotensive activities of Acebutolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Enalapril,Atenolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Atenolol may increase the hypotensive activities of Enalapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Enalapril,Betaxolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Betaxolol may increase the hypotensive activities of Enalapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Enalapril,Bisoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Enalapril may increase the hypotensive activities of Bisoprolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Enalapril,Metoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Metoprolol may increase the hypotensive activities of Enalapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Enalapril,Nebivolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Enalapril may increase the hypotensive activities of Nebivolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Enalapril,Propranolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Propranolol may increase the hypotensive activities of Enalapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Enalapril,Amlodipine,ACEI,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Enalapril,Felodipine,ACEI,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Enalapril,Isradipine,ACEI,CCB,Minor,"DESCRIPTION

Isradipine may increase the hypotensive activities of Enalapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Enalapril,Lercanidipine,ACEI,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Enalapril,Nifedipine,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Enalapril is combined with Nifedipine.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Enalapril,Diltiazem,ACEI,CCB,Minor,"DESCRIPTION

Diltiazem may increase the hypotensive activities of Enalapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Enalapril,Verapamil,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Enalapril is combined with Verapamil.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Enalapril,Hydrochlorothiazide,ACEI,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Enalapril,Indapamide,ACEI,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Enalapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Enalapril,Amiloride,ACEI,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Amiloride is combined with Enalapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Perindopril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Lisinopril is combined with Perindopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Ramipril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Ramipril is combined with Lisinopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Imidapril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Lisinopril is combined with Imidapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Candesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Lisinopril is combined with Candesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Irbesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Lisinopril is combined with Irbesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Losartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Lisinopril is combined with Losartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Telmisartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Lisinopril is combined with Telmisartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Valsartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Lisinopril is combined with Valsartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Olmesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Lisinopril is combined with Olmesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Lisinopril,Acebutolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Lisinopril may increase the hypotensive activities of Acebutolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Lisinopril,Atenolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Atenolol may increase the hypotensive activities of Lisinopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Lisinopril,Betaxolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Betaxolol may increase the hypotensive activities of Lisinopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Lisinopril,Bisoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Bisoprolol may increase the hypotensive activities of Lisinopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Lisinopril,Metoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Metoprolol may increase the hypotensive activities of Lisinopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Lisinopril,Nebivolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Lisinopril may increase the hypotensive activities of Nebivolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Lisinopril,Propranolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Propranolol may increase the hypotensive activities of Lisinopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Lisinopril,Amlodipine,ACEI,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Lisinopril,Felodipine,ACEI,CCB,Minor,"DESCRIPTION

Lisinopril may increase the hypotensive activities of Felodipine.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Lisinopril,Isradipine,ACEI,CCB,Minor,"DESCRIPTION

Isradipine may increase the hypotensive activities of Lisinopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Lisinopril,Lercanidipine,ACEI,CCB,Minor,"DESCRIPTION

Lercanidipine may increase the hypotensive activities of Lisinopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Lisinopril,Nifedipine,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Lisinopril is combined with Nifedipine.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Lisinopril,Diltiazem,ACEI,CCB,Minor,"DESCRIPTION

Diltiazem may increase the hypotensive activities of Lisinopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Lisinopril,Verapamil,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Lisinopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Lisinopril,Hydrochlorothiazide,ACEI,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Lisinopril,Indapamide,ACEI,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Lisinopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Lisinopril,Amiloride,ACEI,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Amiloride is combined with Lisinopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Perindopril,Ramipril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Ramipril is combined with Perindopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Perindopril,Imidapril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Perindopril is combined with Imidapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Perindopril,Candesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindopril is combined with Candesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Perindopril,Irbesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindopril is combined with Irbesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Perindopril,Losartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindopril is combined with Losartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Perindopril,Telmisartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindopril is combined with Telmisartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Perindopril,Valsartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindopril is combined with Valsartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Perindopril,Olmesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindopril is combined with Olmesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Perindopril,Acebutolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Perindopril may increase the hypotensive activities of Acebutolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Perindopril,Atenolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Atenolol may increase the hypotensive activities of Perindopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Perindopril,Betaxolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Betaxolol may increase the hypotensive activities of Perindopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Perindopril,Bisoprolol,ACEI,Beta-Blocker,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Perindopril,Metoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Metoprolol may increase the hypotensive activities of Perindopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Perindopril,Nebivolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Perindopril may increase the hypotensive activities of Nebivolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Perindopril,Propranolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Propranolol may increase the hypotensive activities of Perindopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Perindopril,Amlodipine,ACEI,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Perindopril,Felodipine,ACEI,CCB,Minor,"DESCRIPTION

Perindopril may increase the hypotensive activities of Felodipine.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Perindopril,Isradipine,ACEI,CCB,Minor,"DESCRIPTION

Isradipine may increase the hypotensive activities of Perindopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Perindopril,Lercanidipine,ACEI,CCB,Minor,"DESCRIPTION

Lercanidipine may increase the hypotensive activities of Perindopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Perindopril,Nifedipine,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Perindopril is combined with Nifedipine.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Perindopril,Diltiazem,ACEI,CCB,Minor,"DESCRIPTION

Diltiazem may increase the hypotensive activities of Perindopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Perindopril,Verapamil,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Perindopril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Perindopril,Hydrochlorothiazide,ACEI,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Perindopril can be increased when used in combination with Hydrochlorothiazide.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Perindopril,Indapamide,ACEI,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Perindopril,Amiloride,ACEI,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Amiloride is combined with Perindopril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Ramipril,Imidapril,ACEI,ACEI,Moderate,"DESCRIPTION

The risk or severity of angioedema can be increased when Ramipril is combined with Imidapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Ramipril,Candesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ramipril is combined with Candesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Ramipril,Irbesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ramipril is combined with Irbesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Ramipril,Losartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ramipril is combined with Losartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Ramipril,Telmisartan,ACEI,ARB,Major,"DESCRIPTION

The risk or severity of adverse effects can be increased when Telmisartan is combined with Ramipril.",Major,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Ramipril,Valsartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ramipril is combined with Valsartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Ramipril,Olmesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ramipril is combined with Olmesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Ramipril,Acebutolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Acebutolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Ramipril,Atenolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Atenolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Ramipril,Betaxolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Betaxolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Ramipril,Bisoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Bisoprolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Ramipril,Metoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Metoprolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Ramipril,Nebivolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Nebivolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Ramipril,Propranolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Propranolol.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Ramipril,Amlodipine,ACEI,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Ramipril,Felodipine,ACEI,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Ramipril,Isradipine,ACEI,CCB,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Isradipine.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Ramipril,Lercanidipine,ACEI,CCB,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Lercanidipine.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Ramipril,Nifedipine,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Ramipril is combined with Nifedipine.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Ramipril,Diltiazem,ACEI,CCB,Minor,"DESCRIPTION

Ramipril may increase the hypotensive activities of Diltiazem.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Ramipril,Verapamil,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Ramipril is combined with Verapamil.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Ramipril,Hydrochlorothiazide,ACEI,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Ramipril,Indapamide,ACEI,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Ramipril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Ramipril,Amiloride,ACEI,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Amiloride is combined with Ramipril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Imidapril,Candesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Imidapril is combined with Candesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Imidapril,Irbesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Imidapril is combined with Irbesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Imidapril,Losartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Imidapril is combined with Losartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Imidapril,Telmisartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Imidapril is combined with Telmisartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Imidapril,Valsartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Imidapril is combined with Valsartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Imidapril,Olmesartan,ACEI,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Imidapril is combined with Olmesartan.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Imidapril,Acebutolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Acebutolol may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Imidapril,Atenolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Atenolol may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Imidapril,Betaxolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Betaxolol may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Imidapril,Bisoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Bisoprolol may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Imidapril,Metoprolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Metoprolol may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Imidapril,Nebivolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Nebivolol may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Imidapril,Propranolol,ACEI,Beta-Blocker,Minor,"DESCRIPTION

Propranolol may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Imidapril,Amlodipine,ACEI,CCB,Minor,"DESCRIPTION

Amlodipine may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Imidapril,Felodipine,ACEI,CCB,Minor,"DESCRIPTION

Felodipine may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Imidapril,Isradipine,ACEI,CCB,Minor,"DESCRIPTION

Isradipine may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Imidapril,Lercanidipine,ACEI,CCB,Minor,"DESCRIPTION

Lercanidipine may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Imidapril,Nifedipine,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Nifedipine is combined with Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Imidapril,Diltiazem,ACEI,CCB,Minor,"DESCRIPTION

Diltiazem may increase the hypotensive activities of Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Imidapril,Verapamil,ACEI,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Imidapril.",Minor,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is RECOMMENDED. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ACE Inhibitor helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. ACEIs are superior to ARBs for edema prevention (2.7% vs 3.7% rate). (Sources: Makani et al., 2011; De la Sierra, 2009)."
Imidapril,Hydrochlorothiazide,ACEI,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Imidapril can be increased when used in combination with Hydrochlorothiazide.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Imidapril,Indapamide,ACEI,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Imidapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Imidapril,Amiloride,ACEI,Diuretic,Moderate,"DESCRIPTION
The risk or severity of hyperkalemia can be increased when Amiloride is combined with Imidapril.",Moderate,"Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).","Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ACE Inhibitors are prioritized because meta-analyses indicate they significantly reduce the risk of all-cause mortality and cardiovascular death, whereas ARBs often show no significant effect on these specific outcomes compared to placebo (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ACE Inhibitors carry a 3.2-fold higher risk of dry cough compared to ARBs due to the accumulation of bradykinin. If tolerability becomes a barrier to adherence, ARBs are recommended as the standard alternative (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Candesartan,Irbesartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Irbesartan is combined with Candesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Candesartan,Losartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Losartan is combined with Candesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Candesartan,Telmisartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Candesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Candesartan,Valsartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Valsartan is combined with Candesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Candesartan,Olmesartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Candesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Candesartan,Acebutolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Acebutolol may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Candesartan,Atenolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Atenolol may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Candesartan,Betaxolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Betaxolol may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Candesartan,Bisoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Bisoprolol may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Candesartan,Metoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Metoprolol may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Candesartan,Nebivolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Nebivolol may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Candesartan,Propranolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Propranolol may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Candesartan,Amlodipine,ARB,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Candesartan,Felodipine,ARB,CCB,Moderate,"DESCRIPTION

The metabolism of Candesartan can be decreased when combined with Felodipine.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Candesartan,Isradipine,ARB,CCB,Minor,"DESCRIPTION

Isradipine may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Candesartan,Lercanidipine,ARB,CCB,Minor,"DESCRIPTION

Lercanidipine may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Candesartan,Nifedipine,ARB,CCB,Minor,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Nifedipine is combined with Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Candesartan,Diltiazem,ARB,CCB,Moderate,"DESCRIPTION

The metabolism of Diltiazem can be decreased when combined with Candesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Candesartan,Verapamil,ARB,CCB,Minor,"DESCRIPTION

Verapamil may increase the hypotensive activities of Candesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Candesartan,Hydrochlorothiazide,ARB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Candesartan,Indapamide,ARB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Candesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Candesartan,Amiloride,ARB,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Candesartan is combined with Amiloride.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Irbesartan,Losartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Losartan is combined with Irbesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Irbesartan,Telmisartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Telmisartan is combined with Irbesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Irbesartan,Valsartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Valsartan is combined with Irbesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Irbesartan,Olmesartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Irbesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Irbesartan,Acebutolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Irbesartan may increase the hypotensive activities of Acebutolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Irbesartan,Atenolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Atenolol may increase the hypotensive activities of Irbesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Irbesartan,Betaxolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Betaxolol may increase the hypotensive activities of Irbesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Irbesartan,Bisoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Bisoprolol may increase the hypotensive activities of Irbesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Irbesartan,Metoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Metoprolol may increase the hypotensive activities of Irbesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Irbesartan,Nebivolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Irbesartan may increase the hypotensive activities of Nebivolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Irbesartan,Propranolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Propranolol may increase the hypotensive activities of Irbesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Irbesartan,Amlodipine,ARB,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Irbesartan,Felodipine,ARB,CCB,Major,"DESCRIPTION

The metabolism of Irbesartan can be decreased when combined with Felodipine.",Major,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Irbesartan,Isradipine,ARB,CCB,Minor,"DESCRIPTION

Isradipine may increase the hypotensive activities of Irbesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Irbesartan,Lercanidipine,ARB,CCB,Minor,"DESCRIPTION

Lercanidipine may increase the hypotensive activities of Irbesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Irbesartan,Nifedipine,ARB,CCB,Minor,"DESCRIPTION

The serum concentration of the active metabolites of Irbesartan can be increased when Irbesartan is used in combination with Nifedipine.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Irbesartan,Diltiazem,ARB,CCB,Moderate,"DESCRIPTION

The metabolism of Irbesartan can be decreased when combined with Diltiazem.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Irbesartan,Verapamil,ARB,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Irbesartan,Hydrochlorothiazide,ARB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Irbesartan,Indapamide,ARB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Irbesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Irbesartan,Amiloride,ARB,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Amiloride.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Losartan,Telmisartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Losartan is combined with Telmisartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Losartan,Valsartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Valsartan is combined with Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Losartan,Olmesartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Losartan,Acebutolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

Losartan may increase the arrhythmogenic activities of Acebutolol.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Losartan,Atenolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

Atenolol may increase the arrhythmogenic activities of Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Losartan,Betaxolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Losartan,Bisoprolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

The therapeutic efficacy of Losartan can be increased when used in combination with Bisoprolol.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Losartan,Metoprolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

Metoprolol may increase the arrhythmogenic activities of Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Losartan,Nebivolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

Losartan may increase the arrhythmogenic activities of Nebivolol.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Losartan,Propranolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

Propranolol may increase the arrhythmogenic activities of Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Losartan,Amlodipine,ARB,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Losartan,Felodipine,ARB,CCB,Moderate,"DESCRIPTION

Losartan may increase the arrhythmogenic activities of Felodipine.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Losartan,Isradipine,ARB,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Losartan,Lercanidipine,ARB,CCB,Moderate,"DESCRIPTION

Lercanidipine may increase the arrhythmogenic activities of Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Losartan,Nifedipine,ARB,CCB,Moderate,"DESCRIPTION

Losartan may increase the arrhythmogenic activities of Nifedipine.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Losartan,Diltiazem,ARB,CCB,Moderate,"DESCRIPTION

Diltiazem may increase the arrhythmogenic activities of Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Losartan,Verapamil,ARB,CCB,Moderate,"DESCRIPTION

Verapamil may increase the arrhythmogenic activities of Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Losartan,Hydrochlorothiazide,ARB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Losartan,Indapamide,ARB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Losartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Losartan,Amiloride,ARB,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Losartan is combined with Amiloride.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Telmisartan,Valsartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Valsartan is combined with Telmisartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Telmisartan,Olmesartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Telmisartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Telmisartan,Acebutolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Telmisartan may increase the hypotensive activities of Acebutolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Telmisartan,Atenolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

Atenolol may decrease the excretion rate of Telmisartan which could result in a higher serum level.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Telmisartan,Betaxolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Betaxolol may increase the hypotensive activities of Telmisartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Telmisartan,Bisoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Bisoprolol may increase the hypotensive activities of Telmisartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Telmisartan,Metoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Metoprolol may increase the hypotensive activities of Telmisartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Telmisartan,Nebivolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

The metabolism of Nebivolol can be decreased when combined with Telmisartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Telmisartan,Propranolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

The serum concentration of Propranolol can be increased when it is combined with Telmisartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Telmisartan,Amlodipine,ARB,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Telmisartan,Felodipine,ARB,CCB,Moderate,"DESCRIPTION

Telmisartan may decrease the excretion rate of Felodipine which could result in a higher serum level.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Telmisartan,Isradipine,ARB,CCB,Moderate,"DESCRIPTION

Isradipine may decrease the excretion rate of Telmisartan which could result in a higher serum level.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Telmisartan,Lercanidipine,ARB,CCB,Minor,"DESCRIPTION

Lercanidipine may increase the hypotensive activities of Telmisartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Telmisartan,Nifedipine,ARB,CCB,Moderate,"DESCRIPTION

Telmisartan may decrease the excretion rate of Nifedipine which could result in a higher serum level.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Telmisartan,Diltiazem,ARB,CCB,Minor,"DESCRIPTION

Diltiazem may increase the hypotensive activities of Telmisartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Telmisartan,Verapamil,ARB,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Telmisartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Telmisartan,Hydrochlorothiazide,ARB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Telmisartan,Indapamide,ARB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Telmisartan,Amiloride,ARB,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Amiloride.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Valsartan,Olmesartan,ARB,ARB,Moderate,"DESCRIPTION

The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Valsartan is combined with Olmesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Valsartan,Acebutolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Valsartan may increase the hypotensive activities of Acebutolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Valsartan,Atenolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Valsartan may increase the hypotensive activities of Atenolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Valsartan,Betaxolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Valsartan may increase the hypotensive activities of Betaxolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Valsartan,Bisoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Valsartan may increase the hypotensive activities of Bisoprolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Valsartan,Metoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Valsartan may increase the hypotensive activities of Metoprolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Valsartan,Nebivolol,ARB,Beta-Blocker,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Valsartan,Propranolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Valsartan may increase the hypotensive activities of Propranolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Valsartan,Amlodipine,ARB,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Valsartan,Felodipine,ARB,CCB,Moderate,"DESCRIPTION

The metabolism of Valsartan can be decreased when combined with Felodipine.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Valsartan,Isradipine,ARB,CCB,Minor,"DESCRIPTION

Valsartan may increase the hypotensive activities of Isradipine.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Valsartan,Lercanidipine,ARB,CCB,Minor,"DESCRIPTION

Valsartan may increase the hypotensive activities of Lercanidipine.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Valsartan,Nifedipine,ARB,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Valsartan is combined with Nifedipine.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Valsartan,Diltiazem,ARB,CCB,Moderate,"DESCRIPTION

The metabolism of Diltiazem can be decreased when combined with Valsartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Valsartan,Verapamil,ARB,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Valsartan,Hydrochlorothiazide,ARB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Valsartan,Indapamide,ARB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Valsartan,Amiloride,ARB,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Valsartan is combined with Amiloride.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Olmesartan,Acebutolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Olmesartan may increase the hypotensive activities of Acebutolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Olmesartan,Atenolol,ARB,Beta-Blocker,Moderate,"DESCRIPTION

Olmesartan may decrease the excretion rate of Atenolol which could result in a higher serum level.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Olmesartan,Betaxolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Betaxolol may increase the hypotensive activities of Olmesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Olmesartan,Bisoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Olmesartan may increase the hypotensive activities of Bisoprolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Olmesartan,Metoprolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Metoprolol may increase the hypotensive activities of Olmesartan.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Olmesartan,Nebivolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Olmesartan may increase the hypotensive activities of Nebivolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Olmesartan,Propranolol,ARB,Beta-Blocker,Minor,"DESCRIPTION

Olmesartan may increase the hypotensive activities of Propranolol.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Olmesartan,Amlodipine,ARB,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Olmesartan,Felodipine,ARB,CCB,Moderate,"DESCRIPTION

Olmesartan may decrease the excretion rate of Felodipine which could result in a higher serum level.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Olmesartan,Isradipine,ARB,CCB,Moderate,"DESCRIPTION

Olmesartan may decrease the excretion rate of Isradipine which could result in a higher serum level.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Olmesartan,Lercanidipine,ARB,CCB,Minor,"DESCRIPTION

Olmesartan may increase the hypotensive activities of Lercanidipine.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Olmesartan,Nifedipine,ARB,CCB,Moderate,"DESCRIPTION

Olmesartan may decrease the excretion rate of Nifedipine which could result in a higher serum level.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Olmesartan,Diltiazem,ARB,CCB,Minor,"DESCRIPTION

Olmesartan may increase the hypotensive activities of Diltiazem.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Olmesartan,Verapamil,ARB,CCB,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.",Minor,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).","Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009).",,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE C - Combination Therapy] Clinical Note: This Combination Therapy is recommended. Calcium Channel Blockers (CCBs) can cause leg swelling by widening arteries more than veins. The added ARB helps widen the veins, balancing the pressure and reducing swelling risk by ~38%. Note: ACEIs are slightly more effective than ARBs for edema prevention. (Sources: Makani et al., 2011; De la Sierra, 2009)."
Olmesartan,Hydrochlorothiazide,ARB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Olmesartan,Indapamide,ARB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Olmesartan.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).

[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Olmesartan,Amiloride,ARB,Diuretic,Moderate,"DESCRIPTION

The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Amiloride.",Moderate,"Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).","Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006).",,,,"[RULE A - Mortality] Clinical Note: ARBs have no significant effect on all-cause mortality compared to placebo. ACE Inhibitors are preferred for mortality reduction (Source: Alcocer et al., 2023).

[RULE B - Tolerability] Clinical Note: ARBs have a superior tolerability profile with significantly lower risk of dry cough compared to ACE Inhibitors (3.2-fold lower risk). ARBs are the preferred alternative when cough or other ACEI-related side effects limit adherence (Source: Hu et al., 2023; ACCP Guidelines, 2006)."
Acebutolol,Atenolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Atenolol may increase the arrhythmogenic activities of Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Betaxolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Bisoprolol,Beta-Blocker,Beta-Blocker,Major,"DESCRIPTION

The risk or severity of adverse effects can be increased when Bisoprolol is combined with Acebutolol.",Major,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Metoprolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Metoprolol may increase the arrhythmogenic activities of Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Nebivolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Acebutolol may increase the arrhythmogenic activities of Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Propranolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Propranolol may increase the arrhythmogenic activities of Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Amlodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Amlodipine may increase the arrhythmogenic activities of Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Felodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Felodipine may increase the arrhythmogenic activities of Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Isradipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Lercanidipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Lercanidipine may increase the arrhythmogenic activities of Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Nifedipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Diltiazem,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Diltiazem may increase the arrhythmogenic activities of Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Verapamil,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Acebutolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Hydrochlorothiazide,Beta-Blocker,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Acebutolol can be increased when used in combination with Hydrochlorothiazide.",Moderate,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Indapamide,Beta-Blocker,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Acebutolol.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Acebutolol,Amiloride,Beta-Blocker,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Amiloride is combined with Acebutolol.",Minor,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Betaxolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Atenolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Bisoprolol,Beta-Blocker,Beta-Blocker,Major,"DESCRIPTION

The risk or severity of adverse effects can be increased when Bisoprolol is combined with Atenolol.",Major,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Metoprolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Metoprolol may increase the arrhythmogenic activities of Atenolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Nebivolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Atenolol may increase the arrhythmogenic activities of Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Propranolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Atenolol may increase the arrhythmogenic activities of Propranolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Amlodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Atenolol may increase the arrhythmogenic activities of Amlodipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Felodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Atenolol may increase the arrhythmogenic activities of Felodipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Isradipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Atenolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Lercanidipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Atenolol may increase the arrhythmogenic activities of Lercanidipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Nifedipine,Beta-Blocker,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Diltiazem,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Atenolol may increase the arrhythmogenic activities of Diltiazem.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Verapamil,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Atenolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Hydrochlorothiazide,Beta-Blocker,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Indapamide,Beta-Blocker,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Atenolol,Amiloride,Beta-Blocker,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Bisoprolol,Beta-Blocker,Beta-Blocker,Major,"DESCRIPTION

The risk or severity of adverse effects can be increased when Bisoprolol is combined with Betaxolol.",Major,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Metoprolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Metoprolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Nebivolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Propranolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Propranolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Amlodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Amlodipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Felodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Felodipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Isradipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Isradipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Lercanidipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Lercanidipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Nifedipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Betaxolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Diltiazem,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Betaxolol may increase the arrhythmogenic activities of Diltiazem.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Verapamil,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Betaxolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Hydrochlorothiazide,Beta-Blocker,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Betaxolol can be increased when used in combination with Hydrochlorothiazide.",Moderate,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Indapamide,Beta-Blocker,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Betaxolol.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Betaxolol,Amiloride,Beta-Blocker,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Betaxolol is combined with Amiloride.",Minor,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Metoprolol,Beta-Blocker,Beta-Blocker,Major,"DESCRIPTION

The risk or severity of adverse effects can be increased when Bisoprolol is combined with Metoprolol.",Major,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Nebivolol,Beta-Blocker,Beta-Blocker,Major,"DESCRIPTION

The risk or severity of adverse effects can be increased when Bisoprolol is combined with Nebivolol.",Major,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Propranolol,Beta-Blocker,Beta-Blocker,Major,"DESCRIPTION

The risk or severity of adverse effects can be increased when Bisoprolol is combined with Propranolol.",Major,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Amlodipine,Beta-Blocker,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Felodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The therapeutic efficacy of Felodipine can be increased when used in combination with Bisoprolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Isradipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The therapeutic efficacy of Isradipine can be increased when used in combination with Bisoprolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Lercanidipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The therapeutic efficacy of Lercanidipine can be increased when used in combination with Bisoprolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Nifedipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bisoprolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Diltiazem,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The therapeutic efficacy of Diltiazem can be increased when used in combination with Bisoprolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Verapamil,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Bisoprolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Hydrochlorothiazide,Beta-Blocker,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Indapamide,Beta-Blocker,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Bisoprolol.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Bisoprolol,Amiloride,Beta-Blocker,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Amiloride is combined with Bisoprolol.",Minor,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Nebivolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Metoprolol may increase the arrhythmogenic activities of Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Propranolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Metoprolol may increase the arrhythmogenic activities of Propranolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Amlodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Metoprolol may increase the arrhythmogenic activities of Amlodipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Felodipine,Beta-Blocker,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Isradipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Metoprolol may increase the arrhythmogenic activities of Isradipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Lercanidipine,Beta-Blocker,CCB,Minor,"DESCRIPTION

The serum concentration of Lercanidipine can be decreased when it is combined with Metoprolol.",Minor,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Nifedipine,Beta-Blocker,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Diltiazem,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Metoprolol may increase the arrhythmogenic activities of Diltiazem.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Verapamil,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Metoprolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Hydrochlorothiazide,Beta-Blocker,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Indapamide,Beta-Blocker,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Metoprolol.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Metoprolol,Amiloride,Beta-Blocker,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Metoprolol is combined with Amiloride.",Minor,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Propranolol,Beta-Blocker,Beta-Blocker,Moderate,"DESCRIPTION

Propranolol may increase the arrhythmogenic activities of Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Amlodipine,Beta-Blocker,CCB,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Felodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Felodipine may increase the arrhythmogenic activities of Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Isradipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Lercanidipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Lercanidipine may increase the arrhythmogenic activities of Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Nifedipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Diltiazem,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Diltiazem may increase the arrhythmogenic activities of Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Verapamil,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Nebivolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Hydrochlorothiazide,Beta-Blocker,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Indapamide,Beta-Blocker,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Nebivolol.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Nebivolol,Amiloride,Beta-Blocker,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Amiloride is combined with Nebivolol.",Minor,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Amlodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Amlodipine may increase the arrhythmogenic activities of Propranolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Felodipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Propranolol may increase the arrhythmogenic activities of Felodipine.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Isradipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Propranolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Lercanidipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Lercanidipine may increase the arrhythmogenic activities of Propranolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Nifedipine,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Propranolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Diltiazem,Beta-Blocker,CCB,Moderate,"DESCRIPTION

Diltiazem may increase the arrhythmogenic activities of Propranolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Verapamil,Beta-Blocker,CCB,Moderate,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Propranolol.",Moderate,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Hydrochlorothiazide,Beta-Blocker,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Indapamide,Beta-Blocker,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Propranolol.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).","Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).

[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Propranolol,Amiloride,Beta-Blocker,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Propranolol is combined with Amiloride.",Minor,,,,,"Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022).","[RULE E - Beta-Blocker Phenotype] Clinical Note: Beta-blockers are one of the five major antihypertensive classes, specifically indicated for patients with a fast resting heart rate (>80 bpm) to target sympathetic overactivity (stress signals). They are also preferred for managing comorbidities like anxiety or arrhythmias (Source: Mahfoud et al., 2024; Mancia et al., 2022)."
Amlodipine,Felodipine,CCB,CCB,Moderate,"DESCRIPTION

Amlodipine may increase the arrhythmogenic activities of Felodipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Amlodipine,Isradipine,CCB,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Amlodipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Amlodipine,Lercanidipine,CCB,CCB,Moderate,"DESCRIPTION

Amlodipine may increase the arrhythmogenic activities of Lercanidipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Amlodipine,Nifedipine,CCB,CCB,Moderate,"DESCRIPTION

Amlodipine may increase the arrhythmogenic activities of Nifedipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Amlodipine,Diltiazem,CCB,CCB,Moderate,"DESCRIPTION

Diltiazem may increase the arrhythmogenic activities of Amlodipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Amlodipine,Verapamil,CCB,CCB,Moderate,"DESCRIPTION

Amlodipine may increase the arrhythmogenic activities of Verapamil.",Moderate,,,,,,No specific XAI rules apply to this combination.
Amlodipine,Hydrochlorothiazide,CCB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Amlodipine,Indapamide,CCB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Amlodipine,Amiloride,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Amlodipine is combined with Amiloride.",Minor,,,,,,No specific XAI rules apply to this combination.
Felodipine,Isradipine,CCB,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Felodipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Felodipine,Lercanidipine,CCB,CCB,Moderate,"DESCRIPTION

Lercanidipine may increase the arrhythmogenic activities of Felodipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Felodipine,Nifedipine,CCB,CCB,Moderate,"DESCRIPTION

Felodipine may increase the arrhythmogenic activities of Nifedipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Felodipine,Diltiazem,CCB,CCB,Moderate,"DESCRIPTION

Diltiazem may increase the arrhythmogenic activities of Felodipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Felodipine,Verapamil,CCB,CCB,Moderate,"DESCRIPTION

Verapamil may increase the arrhythmogenic activities of Felodipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Felodipine,Hydrochlorothiazide,CCB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Felodipine can be increased when used in combination with Hydrochlorothiazide.",Moderate,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Felodipine,Indapamide,CCB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Felodipine.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Felodipine,Amiloride,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Amiloride is combined with Felodipine.",Minor,,,,,,No specific XAI rules apply to this combination.
Isradipine,Lercanidipine,CCB,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Lercanidipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Isradipine,Nifedipine,CCB,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Nifedipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Isradipine,Diltiazem,CCB,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Diltiazem.",Moderate,,,,,,No specific XAI rules apply to this combination.
Isradipine,Verapamil,CCB,CCB,Moderate,"DESCRIPTION

Isradipine may increase the arrhythmogenic activities of Verapamil.",Moderate,,,,,,No specific XAI rules apply to this combination.
Isradipine,Hydrochlorothiazide,CCB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Isradipine can be increased when used in combination with Hydrochlorothiazide.",Moderate,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Isradipine,Indapamide,CCB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Isradipine.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Isradipine,Amiloride,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Isradipine is combined with Amiloride.",Minor,,,,,,No specific XAI rules apply to this combination.
Lercanidipine,Nifedipine,CCB,CCB,Moderate,"DESCRIPTION

Lercanidipine may increase the arrhythmogenic activities of Nifedipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Lercanidipine,Diltiazem,CCB,CCB,Moderate,"DESCRIPTION

Diltiazem may increase the arrhythmogenic activities of Lercanidipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Lercanidipine,Verapamil,CCB,CCB,Moderate,"DESCRIPTION

Lercanidipine may increase the arrhythmogenic activities of Verapamil.",Moderate,,,,,,No specific XAI rules apply to this combination.
Lercanidipine,Hydrochlorothiazide,CCB,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Lercanidipine,Indapamide,CCB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Lercanidipine.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Lercanidipine,Amiloride,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Lercanidipine is combined with Amiloride.",Minor,,,,,,No specific XAI rules apply to this combination.
Nifedipine,Diltiazem,CCB,CCB,Moderate,"DESCRIPTION

The serum concentration of Nifedipine can be increased when it is combined with Diltiazem.",Moderate,,,,,,No specific XAI rules apply to this combination.
Nifedipine,Verapamil,CCB,CCB,Moderate,"DESCRIPTION

Verapamil may increase the arrhythmogenic activities of Nifedipine.",Moderate,,,,,,No specific XAI rules apply to this combination.
Nifedipine,Hydrochlorothiazide,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Nifedipine.",Minor,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Nifedipine,Indapamide,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of QTc prolongation can be increased when Indapamide is combined with Nifedipine.",Minor,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Nifedipine,Amiloride,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Amiloride is combined with Nifedipine.",Minor,,,,,,No specific XAI rules apply to this combination.
Diltiazem,Verapamil,CCB,CCB,Moderate,"DESCRIPTION

Diltiazem may increase the arrhythmogenic activities of Verapamil.",Moderate,,,,,,No specific XAI rules apply to this combination.
Diltiazem,Hydrochlorothiazide,CCB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Diltiazem can be increased when used in combination with Hydrochlorothiazide.",Moderate,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Diltiazem,Indapamide,CCB,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Diltiazem.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Diltiazem,Amiloride,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Diltiazem is combined with Amiloride.",Minor,,,,,,No specific XAI rules apply to this combination.
Verapamil,Hydrochlorothiazide,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.",Minor,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Verapamil,Indapamide,CCB,Diuretic,Moderate,"DESCRIPTION

The metabolism of Indapamide can be decreased when combined with Verapamil.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Verapamil,Amiloride,CCB,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Amiloride is combined with Verapamil.",Minor,,,,,,No specific XAI rules apply to this combination.
Hydrochlorothiazide,Indapamide,Diuretic,Diuretic,Moderate,"DESCRIPTION

The therapeutic efficacy of Indapamide can be increased when used in combination with Hydrochlorothiazide.",Moderate,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Hydrochlorothiazide,Amiloride,Diuretic,Diuretic,,"Warning: 

There were no interactions found. It does not necessarily mean that no interactions exist.",NoInteraction,,,,"Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Hydrochlorothiazide (HCTZ) has inferior cardiovascular protection compared to Indapamide. Meta-analyses show HCTZ fails to significantly reduce mortality, stroke, or heart failure. Consider switching to Indapamide for superior outcomes (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
Indapamide,Amiloride,Diuretic,Diuretic,Minor,"DESCRIPTION

The risk or severity of adverse effects can be increased when Amiloride is combined with Indapamide.",Minor,,,,"Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019).",,"[RULE D - Diuretic Efficacy] Clinical Note: Indapamide is prioritized over Hydrochlorothiazide (HCTZ) because meta-analyses demonstrate it significantly reduces all-cause mortality, stroke, and heart failure, whereas HCTZ fails to consistently show these benefits and offers inferior 24-hour blood pressure control (Source: Roush et al., 2015; Mishra, 2016; Burnier et al., 2019)."
